These include situations where metformin is ineffective, contraindicated, or when patients fail to reach their target glycemic control despite treatment with metformin and other medications
Common, usually mild: Injection-site reactions (redness, bruising, mild swelling), most frequent Mild fluid retention in the first 12 weeks as IGF-1 rises Joint stiffness or mild arthralgia Headache or flushing after injection Less common, dose- or response-related: Carpal-tunnel-like wrist symptoms (sign IGF-1 may be too high) Elevated fasting glucose / mild insulin resistance, GH antagonizes insulin Peripheral edema persisting beyond the first few weeks Skin sensitivity at injection sites The monitoring that matters
Survey recruitment took place via an online portal, in app, and via email
Semaglutide alters gut microbiota and improves NAFLD in db/db mice
Diabetes Care 44(Supplement 1):S40S52